Skip to main content
ILYANG PHARMACEUTICAL CO.,LTD logo

ILYANG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 007570 ISIN · KR7007570005 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2024-03-07 AGM Information
Country KR South Korea
Listing KO 007570

About ILYANG PHARMACEUTICAL CO.,LTD

https://www.ilyang.co.kr

Ilyang Pharmaceutical, established in 1946, is a research-oriented company that develops and manufactures a diverse portfolio of pharmaceutical products. The company focuses on developing new chemical entities (NCEs) and produces a range of medicines targeting digestive, respiratory, and circulatory system disorders, as well as neoplasms and infectious diseases. Key developments include 'Ilaprazole' (Noltec), a proton pump inhibitor for acid-related disorders, and 'Supect' (Radotinib), a treatment for chronic myeloid leukemia. Its product line also encompasses general drugs, antibiotics, anti-inflammatory agents, nutritional supplements, and well-established consumer health brands like the digestive aid 'NORUMO' and the nutritional drink 'Wonbi-D'.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal notification filed with the Korea Exchange (KRX) regarding the company's decision to hold its Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling and mentions compliance with corporate governance programs. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2024-03-07 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is an official announcement from Il-Yang Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend total, the record date, and the board resolution date. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2024-02-08 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Ilyang Pharmaceutical) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for reporting preliminary financial results before the final audited report is released. Since it provides key financial highlights and performance metrics rather than being a full annual report or a simple announcement of a report's publication, it falls under the 'Earnings Release' category. FY 2023
2024-02-01 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure from Il-Yang Pharmaceutical regarding the approval of a Phase 3 clinical trial for the drug Ilaprazole. It details the clinical trial objectives, methodology, and regulatory approval status. Since this is a specific regulatory announcement regarding business operations and clinical development that does not fit into financial reporting, dividend, or governance categories, it is classified as a general regulatory filing.
2024-01-19 Korean
[기재정정]투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Il-Yang Pharmaceutical regarding a correction to a previous disclosure about a Phase 3 clinical trial approval for Ilaprazole. It details the clinical trial parameters, approval dates, and the nature of the correction (a simple typo). As this is a specific regulatory announcement regarding business operations and clinical trial status that does not fit into categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category.
2024-01-19 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the 3rd quarter of the 53rd fiscal year (2023-01-01 to 2023-09-30) for Ilyang Pharmaceutical Co., Ltd. It contains detailed financial statements, management discussion and analysis, and corporate governance information. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.